Sunitinib (Sarcomatrix Therapeutics)

舒尼替尼 (Sarcomatrix Therapeutics)

Report date: 2024/02/06 17:54:43

Base Information

Drug NameSunitinib (Sarcomatrix Therapeutics)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 2 antagonists +[10]

TargetsVascular endothelial growth factor receptor 3Vascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 2 +[9]

Therapy Area/IndicationsBecker muscular dystrophyCardiomyopathiesMuscular Dystrophy, Duchenne

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSarcomatrix Therapeutics Corp

China Registration ClassN/A

Develop Information

Active CompaniesSarcomatrix Therapeutics Corp

Inactive CompaniesN/A

Active IndicationsBecker muscular dystrophyCardiomyopathiesMuscular Dystrophy, Duchenne

Inactive IndicationsN/A

Other Information

ATC CodeN/A